These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8040114)

  • 41. In vitro antimicrobial activities of lactoferrin, its concomitant use with cefpodoxime proxetil and clinical effect of cefpodoxime proxetil.
    Chimura T; Hirayama T; Nakahara M
    Jpn J Antibiot; 1993 Jun; 46(6):482-5. PubMed ID: 8360983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I; Robbins M; Viljoen L; Brown DF
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Serotype distribution and drug resistance of
    Tian HL; Shi W; Zhou HF; Yuan L; Yao KH; Rexiati D; Xu AM
    Zhonghua Er Ke Za Zhi; 2018 Apr; 56(4):279-283. PubMed ID: 29614568
    [No Abstract]   [Full Text] [Related]  

  • 45. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin].
    Fenoll A; Robledo O; Lerma M; Giménez MJ; Cebrián L; Casal J; Aguilar L; Gómez-Lus ML
    Rev Esp Quimioter; 2006 Mar; 19(1):39-44. PubMed ID: 16688290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cefpodoxime proxetil in upper respiratory tract infections.
    Bergogne-Berezin E
    Drugs; 1991; 42 Suppl 3():25-33. PubMed ID: 1726205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.
    Jones RN; Zurenko GE
    Diagn Microbiol Infect Dis; 1993; 17(4):313-6. PubMed ID: 8112047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefpodoxime: comparable evaluation with other orally available cephalosporins. With a note on the role of beta-lactamases.
    Cullmann W; Dick W
    Zentralbl Bakteriol; 1990 Sep; 273(4):501-17. PubMed ID: 2248685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages.
    Yokota T; Suzuki E; Arai K
    Drugs Exp Clin Res; 1988; 14(8):495-500. PubMed ID: 3073932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antimicrobial activity of cefetamet against clinically isolated microbial strains collected from urban RTI patients].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y
    Jpn J Antibiot; 1992 Nov; 45(11):1451-9. PubMed ID: 1494228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.
    Garrison MW; Malone CL; Eiland JE
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1545-7. PubMed ID: 8726036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antibacterial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections (II)].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1994 Dec; 47(12):1753-61. PubMed ID: 7877255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibacterial activity of cefpodoxime against Branhamella catarrhalis.
    Takenouchi T; Nishino T
    Microbiol Immunol; 1991; 35(12):1059-71. PubMed ID: 1808460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-vitro activities of trospectomycin, cefpodoxime, and second-generation cephalosporins against Haemophilus influenzae type b.
    LiPuma JJ; Daley B; Stull TL
    J Antimicrob Chemother; 1990 Apr; 25(4):535-9. PubMed ID: 2141018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2010)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Apr; 68(2):85-104. PubMed ID: 26182813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2011)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Apr; 68(2):105-24. PubMed ID: 26182814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.